Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31245990 | 0.87 | PDE4B (0.45) | PDE4BSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL31246018 | 0.81 | BRD4 (0.50) | — | |
| SCHEMBL29132125 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL17281971 | 0.71 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL18921640 | 0.70 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL13661148 | 0.70 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL30893488 | 0.69 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL29132081 | 0.68 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL30706089 | 0.68 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL29132176 | 0.68 | GRIN2B (0.48) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702022-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | Halda Therapeutics Opco, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260028338-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2024211684-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028338-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, HCCS | PDE4B 4503/4885SMN1; SMN2 2059/4885CYP2C19 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.